Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhibitory Control Clear all
Terminated Phase 2 Interventional Results available

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

NCT03655236
View directory record Official record
Conditions
Early Parkinson Disease
Interventions
K0706, placebo
Drug · Other
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
50 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329
View directory record Official record
Conditions
Surgery
Interventions
Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Vaping Nicotine on Cognition in Young Adults

NCT04901208
View directory record Official record
Conditions
Nicotine Addiction, Vaping
Interventions
Nicotine pod, Placebo pod
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking

NCT03960138
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Intermittent Theta-burst stimulation (iTBS), Continuous Theta-burst stimulation (cTBS)
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

NCT06029673
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

NCT04112186
View directory record Official record
Conditions
Opiate Use Disorder
Interventions
Behavioral group therapy #1, Behavioral group therapy #2
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 64 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

NCT05906732
View directory record Official record
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo, Dofetilide 250 μg Cap
Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab/Vibostolimab, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

NCT00271765
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
10
States / cities
Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss

NCT00779519
View directory record Official record
Conditions
Obesity
Interventions
TTP435, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

NCT00518765
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Aliskiren plus placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

NCT01258907
View directory record Official record
Conditions
Atherosclerosis
Interventions
MLDL1278A, placebo, statin, stable dose
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
22
States / cities
Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 3, 2026, 11:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Excitability During Self-Paced Voluntary Movements

NCT00017966
View directory record Official record
Conditions
Movement Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

NCT02966834
View directory record Official record
Conditions
Cholestasis
Interventions
Placebo, GSK2330672
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 1 Interventional

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

NCT06948097
View directory record Official record
Conditions
Lung Transplantation
Interventions
fostamatinib, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Stanford, California • Baltimore, Maryland • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy

NCT02971072
View directory record Official record
Conditions
Acute Pain, Atrophic, Goals, Impairment, Infiltration, Injury, Muscle Weakness, Pain, Pathology, Shoulder Pain, Syndrome, Tendinopathy
Interventions
Subacromial injection, Physical Therapy
Procedure · Other
Lead sponsor
University of Oregon
Other
Eligibility
21 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Emotional Processes on Speech Motor Control in Early Childhood Stuttering.

NCT05003583
View directory record Official record
Conditions
Stuttering, Childhood
Interventions
Speaking after viewing pictures with negative and neutral valence
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
3 Years to 10 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Hormonal Influences on Sex Differences in Risk for AUD

NCT04929288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol
Drug
Lead sponsor
Jessica Weafer
Other
Eligibility
21 Years to 26 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa

NCT02997475
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 3, 2026, 11:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nerve Stimulation to Modify a Spinal Reflex

NCT00039819
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:36 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

NCT03273062
View directory record Official record
Conditions
Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions
Tolcapone 200 MG, Placebo
Drug · Other
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Results available

Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding

NCT01632280
View directory record Official record
Conditions
Obesity
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 3, 2026, 11:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Translational Investigation of Growth and Everyday Routines in Kids (TIGER Kids) Fitness Ancillary

NCT03611296
View directory record Official record
Conditions
Childhood Obesity
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
10 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral Mechanism of Energy Compensation With Exercise

NCT04651218
View directory record Official record
Conditions
Obesity, Weight Loss, Eating Behavior
Interventions
exericse
Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 3, 2026, 11:36 AM EDT